The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice

Binary combinations of cisplatin and the 5-HT3 antagonist, BRL 43694, have been used to treat both conventional mice bearing either L1210 leukaemia or ADJ/PC6 plasmacytoma and nude mice xenografted with a human ovarian carcinoma (HX/110). In no case was there evidence for antagonism by the antiemeti...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1990-01, Vol.25 (5), p.377-379
Main Authors: Goddard, P M, Jones, M, Pollard, L A, Valenti, M R, Harrap, K R
Format: Article
Language:English
Subjects:
Animals
Cisplatin - administration & dosage
Cisplatin - therapeutic use
Drug Interactions
Drug Therapy, Combination
Granisetron
Indazoles - administration & dosage
Indazoles - therapeutic use
Leukemia L1210 - drug therapy
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasm Transplantation
Neoplasms, Experimental - drug therapy
Plasmacytoma - drug therapy
Pyrazoles - therapeutic use
Serotonin Antagonists - administration & dosage
Serotonin Antagonists - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Binary combinations of cisplatin and the 5-HT3 antagonist, BRL 43694, have been used to treat both conventional mice bearing either L1210 leukaemia or ADJ/PC6 plasmacytoma and nude mice xenografted with a human ovarian carcinoma (HX/110). In no case was there evidence for antagonism by the antiemetic of the antitumour properties of cisplatin.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00686242